Search Results

DEINOVE announces that a poster titled « DNV3837, a parenteral GI tract-targeted treatment for Clostridioides difficile infection » is to be presented at the ESCMID/ASM conference taking place in Dublin, from October 4 to 7.

DEINOVE announces that its Board of Directors has approved the consolidated financial statements for the year 2021.

DEINOVE (Euronext Growth Paris, ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, announced today that the independent Data Safety Monitoring Board (DSMB) has completed its review of the safety data from the first part of the Phase II clinical trial of DNV3837 in the treatment of Clostridioides difficile infection (CDI).

The new DEINOVE website displays an updated presentation of DEINOVE’s corporate activities and identity

CALIBR is a division of the Scripps Research, a California non-profit corporation, dedicated to finding new treatments addressing unmet medical needs;